Clinical Trials · NCT04809220
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 591
- Start date
- Apr 2021
- Locations
- 44 sites, Japan
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26